anubhai
Back Office| Integris Medtech Ltd |
|---|
| Registered Office: 1st Flr Metro Tower LSC M.O.R, Land New Rajinder Nagar, New Delhi - 110060, New Delhi |
| Phone: 1 |
| Email: 1 |
| Website: 1 |
| Initial public offering of up to [*] equity shares of face value of Re.1/- each ("equity shares") of Integris Medtech Limited (formerly known as Integris Health Private Limited) (the "company" or the "company") for cash at a price of Rs.[*] per equity share (including a premium of Rs.[*] per equity share) ("offer price") aggregating up to Rs.[*] crores (the "offer") comprising a fresh issue of up to [*] equity shares of face value of Re.1/- each aggregating up to Rs.925.00 crores (the "fresh issue") and an offer for sale (the "offer for sale") of up to 21,674,531 equity shares of face value of Re.1/- each aggregating up to Rs.[*] crores comprising up to 15,174,251 equity shares of face value of Re.1/- each aggregating up to Rs.[*] crores by Evercure Holdings Pte. Ltd., up to 3,250,140 equity shares of face value of Re.1/- each aggregating up to Rs.[*] crores by Gurmit Singh Chugh and up to 3,250,140 equity shares of face value Re.1/- each aggregating up to Rs.[*] crores by Punita Sharma (collectively, "promoter selling shareholders" and such shares, the "offered shares"). The company, in consultation with the book running lead managers, may consider a pre-ipo placement of equity shares, as may be permitted under the applicable law, at its discretion, aggregating up to Rs. 185.00 crores, prior to filing of the pre-ipo placement, if undertaken, will be at a price to be determined by the company, in consultation with the brlms. If the pre-ipo placement is completed, the amount raised pursuant to the pre-ipo placement will be reduced from the fresh issue, subject to compliance with Rule 19(2)(b) of the securities contracts (Regulation) rules, 1957, as amended. The pre-ipo placement, if undertaken, shall not exceed 20% of the size of the fresh issue. prior to the completion of the offer, the company shall appropriately intimate the subscribers to the pre-ipo placement, prior to allotment pursuant to the pre-ipo placement, that there is no guarantee that the company may proceed with the offer or the offer may be successful and will result into listing of the equity shares on the stock exchanges. Further, relevant disclosures in relation to such intimation to the subscribers to the pre-ipo placement (if undertaken). The face value of equity shares is Rs.1 each. The offer price is [*] times the face value of the equity shares. The price band and the minimum bid lot shall be decided by the company. |
| Issue | Money Payable On | ||
|---|---|---|---|
| Opens On | Closes On | Application | Allotment |
| 01-Jan-1970 | 01-Jan-1970 | 0.00 - 0.00 | 0.00 - 0.00 |
| Cr. | Lead Managers to the Issue |
|---|---|
| Project Cost | 0.00 |
| Project Financed through Current Offer | 0.00 |
| Post Issue Equity Share Capital | 0.00 |
| Issue Price | 0.00 |
| Projects |
|---|
| Repayment/ prepayment, in full or in part, of certain outstanding borrowings, interest accrued and prepayment penalties, as applicable, availed by: |
| Its wholly-owned Subsidiaries, namely, Translumina Therapeutics, Transhealth and HaleMed Medical Private Limited |
| Its step-down Subsidiaries companies |
| General corporate purposes |
| Promoted By |
|---|
| Evercure Holdings Pte. Ltd. |
| Medicore Holdings Pte. Ltd. |
| Gurmit Singh Chugh |
| BSE |
| NSE |
| Registrar to the Issue |
|---|